Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Years and Older
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Janssen Vaccines and Prevention B.V
- 13 Apr 2023 Status changed from active, no longer recruiting to completed.
- 16 Mar 2023 This trial has been completed in Belgium (End Date: 03 Mar 2023), according to European Clinical Trials Database record.
- 14 Feb 2023 Planned End Date changed from 3 Feb 2023 to 4 Mar 2023.